Dolan Oliver sold $69 of KRRO
Dolan Oliver (Senior Vice President, Finance) sold 5 shares of Korro Bio, Inc. (KRRO) at $13.72 on 2026-09-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is a routine 10b5‑1 sale with negligible market impact.
Market read
Small insider sale; unlikely to affect price or trading decisions.
What to watch
Potential upcoming corporate events or financing that may affect future insider activity.
Background
Form 4 filing discloses insider transactions required by SEC regulations.
Ticker impact
Senior Vice President of Finance sold 5 shares for $68.58 via a pre‑arranged 10b5‑1 plan on Sep 11, 2026.
minor downward pressure
Sale size is trivial relative to holdings; insider is using a 10b5‑1 plan, suggesting no urgent need to liquidate.
Market effects
No significant impact on the biotech sector; typical insider sale.
Limited to U.S. investors tracking KRRO.
Minimal global relevance.
Counterpoint
The sale could be a routine portfolio rebalancing and not a negative signal.
Key entities
- CompanyKorro Bio, Inc.
Biotech firm listed on Nasdaq under KRRO.
- InsiderDolan Oliver
Senior Vice President, Finance at Korro Bio.